Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT followed by neoadjuvant and adjuvant iparomlimab + tuvonralimab in resectable stage IIB–IIIB NSCLC
ChiCTR2500105709Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoints: Major pathological response and Pathological complete response. Started Jul 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500105709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105709.